Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624686 | 1.00 | CHRNA7 (0.61) | CHRNA7CSNK1E | |
| SCHEMBL5354493 | 0.84 | CHRNA7 (0.45) | CHRNA7CSNK1E | |
| SCHEMBL1792911 | 0.84 | CHRNA7 (0.48) | CHRNA7 | |
| SCHEMBL18291307 | 0.79 | CHRNB2 (0.59) | — | |
| SCHEMBL6625406 | 0.79 | CHRNB2 (0.61) | — | |
| SCHEMBL2963520 | 0.79 | CHRNB2 (0.61) | — | |
| SCHEMBL5034127 | 0.79 | CHRNB2 (0.61) | — | |
| SCHEMBL20038439 | 0.79 | CHRNB2 (0.48) | — | |
| SCHEMBL18291726 | 0.79 | CHRNB2 (0.59) | — | |
| Hydrochloric Acid SCHEMBL7250231 | 0.78 | CHRNB2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619205-B1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | ABBVIE BAHAMAS LTD (BS) | 2017-05-17 | — | — | EP | disclosed |
| US-9464078-B2 | Monohydrate of azaadamantane derivatives | ABBVIE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150239882-A1 | NOVEL MONOHYDRATE OF AZAADAMANTANE DERIVATIVES | ABBVIE INC. | 2015-08-27 | — | — | US | disclosed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8853241-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2431368-B1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBVIE BAHAMAS LTD (BS) | 2014-08-27 | — | — | EP | disclosed |
| EP-2443122-B1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20080262023-A1 | Aminomethyl Azaadamantane Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080255180-A1 | 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | CHRNA7 1/4885CSNK1E 1908/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CHRNA7 2432/4885CSNK1E 1348/4885 |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | CHRNA7 2776/4885CSNK1E 3481/4885 |
| US-20080255180-A1 | 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof | UGT1A4, CYP4B1, CYP4A11 | CHRNA7 1518/4885CSNK1E 1569/4885 |
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | NAAA, AADAC, CD38 | CHRNA7 572/4885CSNK1E 1605/4885 |
| US-20150239882-A1 | NOVEL MONOHYDRATE OF AZAADAMANTANE DERIVATIVES | ACMSD, IDH3A, CYP51A1 | CHRNA7 1533/4885CSNK1E 1563/4885 |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | HTT, ACHE, CHRNA10 | CHRNA7 6/4885CSNK1E 2952/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CHRNA7 1/4885CSNK1E 2258/4885 |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | CHRNA7 1034/4885CSNK1E 902/4885 |
| US-20080262023-A1 | Aminomethyl Azaadamantane Derivatives and Methods of Use Thereof | TET3, DNMT1, TET1 | CHRNA7 2401/4885CSNK1E 636/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | CHRNA7 1/4885CSNK1E 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.